Regulatory Submission Approval Time KPI

Regulatory Submission Approval Time is a critical performance indicator that reflects the efficiency of compliance processes.

Streamlined approval timelines enhance operational efficiency, reduce costs, and improve financial health.

Organizations that master this KPI can better align their strategic objectives with regulatory requirements, leading to faster market entry for new products.

A reduction in approval time can also enhance stakeholder confidence and drive a positive ROI metric.

By optimizing this key figure, companies can ensure timely responses to regulatory changes, ultimately supporting sustainable growth.

How Regulatory Submission Approval Time Connects to Your Strategy

Regulatory Submission Approval Time appears in KPI Depot's Life Sciences KPI group, where it ranks fifth among roughly sixty metrics led by R&D Spend as a Percentage of Sales, Clinical Trial Success Rate, and Time to Market for New Drugs. A fifth-place rank in a group that large marks it as a genuine priority, and its neighbors explain why: the metrics above it are the ones a slow approval directly delays.

Its balanced scorecard perspective is internal process, and it is a cycle-time measure of a process the company only partly controls, since the regulator, not the sponsor, sets much of the clock. That makes it a leading signal for the growth metrics it sits beneath, above all Time to Market for New Drugs, of which approval time is one large component. The tension worth naming runs against the safety and quality metrics lower in the same KPI group, Drug Safety Incident Rate and Pharmacovigilance Compliance Rate, and against Clinical Trial Success Rate. Filing sooner or leaner to shorten approval time can push submissions before the evidence is fully mature, which surfaces later as review queries, safety findings, or a failed submission. Read approval time against Clinical Trial Success Rate and the safety metrics, because an approval bought by rushing the dossier is borrowed from the review cycles and incidents that follow.

Measuring Regulatory Submission Approval Time in Practice

The formula is the average time from submission to approval, and the honest work is deciding where the clock starts, where it stops, and which submissions are even eligible to be counted.

The data lives in regulatory affairs tracking systems and the correspondence log with each agency, and joining it honestly means agreeing on the events that bound the interval. Decide whether the clock runs on calendar time or pauses during clock stops, the periods when the regulator has returned questions and is waiting on the sponsor. A review-time figure that excludes those pauses describes the agency's speed; a total-elapsed figure describes the sponsor's experience, and they are not interchangeable. Decide too whether approval means first-cycle approval or approval after any number of review rounds, since counting only clean first-cycle approvals tells a very different story from one that includes resubmissions.

The pitfall that distorts this metric most is censoring. An average computed only over submissions that have already been approved silently drops every submission still stuck in review, which are exactly the slow ones, so the reported figure flatters a pipeline whose worst cases have not resolved yet. Segment by pathway, product type, and agency, because a blended average across drugs and devices, or across regulators, hides the differences that actually drive the timeline.

Common Pitfalls

Many organizations underestimate the impact of inefficient submission processes on overall performance.

• Relying on outdated compliance frameworks can hinder timely approvals. Legacy systems often lack the agility needed to adapt to evolving regulatory landscapes, leading to delays.
• Neglecting cross-departmental collaboration results in miscommunication. When teams operate in silos, critical information may be lost, causing unnecessary back-and-forth with regulators.
• Failing to invest in training for compliance staff can lead to errors. Inadequately trained personnel may overlook essential documentation, prolonging approval times.
• Overcomplicating submission formats can confuse regulators. Clear and concise documentation is vital for expediting approvals and minimizing requests for additional information.

Improvement Levers

Enhancing Regulatory Submission Approval Time requires a focused approach to streamline processes and improve communication.

• Implement a centralized document management system to ensure easy access to submission materials. This reduces search time and enhances collaboration among teams.
• Regularly review and update compliance protocols to align with current regulations. Staying informed about regulatory changes helps prevent delays caused by outdated practices.
• Foster strong relationships with regulatory agencies to facilitate smoother interactions. Open lines of communication can expedite responses and clarify requirements.
• Utilize data-driven decision-making to identify bottlenecks in the approval process. Analyzing historical data can reveal patterns and inform process improvements.

KPI Depot is trusted by consulting, strategy, finance, and analytics teams at leading organizations worldwide, including those listed below.

Regulatory Submission Approval Time Benchmarks

We have 2 relevant benchmarks in our benchmarks database.

Browse the Top Benchmarked KPIs in Life Sciences

Reading the Benchmarks for Regulatory Submission Approval Time

KPI Depot tracks two sources here, and the first thing to notice is that they do not measure the same regulatory process. One reports on submissions from the largest global pharmaceutical companies, where the clock is a new-drug review; the other reports on a United States medical-device clearance route, which is a different pathway with a different statutory timeline and a different meaning of approval. A figure from one cannot stand in for the other, and neither describes a European filing.

With only two sources and no shared definition, read each for how it is built rather than as an industry norm. Before trusting any external approval-time figure, verify three things: the pathway and product type, because a new-drug application, a generic filing, and a device clearance run on unrelated clocks; the geography and agency, since review timelines differ by regulator; and, most important, what the clock actually counts. Some figures measure only the regulator's review time, while others measure total elapsed time including the period the sponsor spends answering queries, and the two can differ enough to make a comparison meaningless.

OKRs That Use Regulatory Submission Approval Time

The Life Sciences KPI group makes this metric an explicit key result. Its OKRs include an objective to accelerate clinical development while maintaining patient safety and regulatory compliance, and Regulatory Submission Approval Time sits under it alongside Patient Recruitment Rates for Clinical Trials, Drug Safety Incident Rate, and Pharmacovigilance Compliance Rate, with the team's direction being to shorten approval time while safety and compliance hold or improve.

The group's OKR guidance reinforces the framing, advising teams to incorporate regulatory timelines explicitly and to pair this KPI with readiness measures so the goal is to remove bottlenecks rather than to cut corners. That pairing is the structural point: approval time is laddered to an objective that also commits to safety and compliance, so a faster clock reflects a cleaner submission rather than a rushed one. Any specific timeline a team commits to is an internal goal against its own pipeline and regulators, not a benchmark level.

See OKR Examples for Life Sciences

Free Whitepaper

Want to achieve performance excellence in Life Sciences? Download our in-depth whitepaper: Definitive Guide to Life Sciences KPIs.

Download the Free Guide

KPI Categories

This KPI is associated with the following categories and industries in our KPI database: